Lasa Supergenerics Limited (BOM:540702)

Market Cap	381.77M -61.3%
Revenue (ttm)	669.61M -47.8%
Net Income	-442.17M
EPS	-9.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,253
Average Volume	16,206
Open	7.62
Previous Close	7.61
Day's Range	7.60 - 7.69
52-Week Range	5.65 - 19.65
Beta	n/a
RSI	55.62
Earnings Date	May 26, 2026

About Lasa Supergenerics

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, s...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2016
• Employees: 66
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540702

Financial Performance

In fiscal year 2025, Lasa Supergenerics's revenue was 1.47 billion, an increase of 41.20% compared to the previous year's 1.04 billion. Losses were -147.57 million, -32.09% less than in 2024.